Form 4 for MBX MBX Biosciences, Inc.
Accepted 2026-08-05 16:57:04 ET · period of report 2026-08-04 · accession 0001193125-26-335373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 16:57 | 2026-08-04 | MBX | Azoulay Salomon | Chief Medical Off | S - Sale | $65.77 | -370 | 14.4K | -3% | -$24.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-04 | S | D | 370 | $65.77 | 14,399 | D | — | — | (F1) The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. (F2) The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. |